Singapore, Aug. 28 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
Curie Oncology (Farrer)
National Cancer Centre
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr John Chia Whay Kuang
Dr Chay Wen Yee
Dr David Tan Shao Peng
Published by HT Di...